Occupational Exposure in the Lombardy Region (Italy) to SARS-CoV-2 Infection: Results from the MUSTANG–OCCUPATION–COVID-19 Study

Valle, Paola Della; Fabbri, Marco; Madotto, Fabiana; Ferrara, Pietro; Cozzolino, Paolo; Calabretto, Elisabetta; D’Orso, M; Longhi, Ermanno; Polosa, Riccardo; Riva, Michele Augusto; Mazzaglia, Giampiero; Sommese, Carmen; Mantovani, L.G.

doi:10.3390/ijerph18052567

Cited by 21 publications

(35 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, Keehner and coll highlighted important differences between the HCW populations and BNT162b2-trial participants, such as the availability of regular testing—irrespectively of symptoms’ occurrence—and the younger age of the HCWs compared with the trial participants [ 1 , 9 ]. It should be also remarked the higher risk of SARS-CoV-2 exposure for hospital workers compared with the general population [ 2 , 3 ]. In addition, it is possible that those individuals with a PCR-positive swab before day 15 may not have already developed an efficacious immune response.…”

Section: Discussionmentioning

confidence: 99%

“…After a positive assessment of safety and efficacy for BNT162b2 mRNA vaccine granted by different national and international regulatory agencies, a global vaccination campaigns targeted healthcare workers (HCWs) as the first vaccinees, both for ensuring their protection and safety at work, and the sustainability of healthcare systems [ 2 , 3 ]. Growing evidence is emerging about the vaccine response, but data on effectiveness and safety after the second dose deserve careful evaluation [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up

et al. 2021

Self Cite

View full text Add to dashboard Cite

This study investigated the response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers (HCWs) in an Italian teaching hospital. 444 participants were surveyed with either multiple RT-PCR assays for detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs or serology testing for the research of virus-specific immunoglobulins. Adverse events following immunization (AEFI) were reported. Two weeks after the first dose anti-SARS-CoV-2 antibodies exceeded reactivity cut-off in 82.5% the participants. Four HCWs tested positive at nasopharyngeal swab after 3 months. More than three-quarters reported AEFIs. Our findings offer an insight regarding the vaccine response after 3 months from its administration, with a special focus on effectiveness data, as well as the type and number of AEFIs complained by HCW recipients. The presented study may serve as reference for future research which will be necessary to explore the long-term safety of this vaccine, especially in population at high risk for infection, such as HCWs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Epidemiological surveillance has primarily focused on hospitalized patients with severe disease, and, as such, the full spectrum of the disease, including the extent and proportion of mild or asymptomatic infections is less clear. Evidence suggests that asymptomatic or oligo-symptomatic infection is not uncommon (7-10). A recent review reported that at least one third of SARS-CoV-2 infections are asymptomatic and that almost three quarters of persons who are asymptomatic at the time of a positive PCR test result will remain asymptomatic (11).…”

Section: Scientific Backgroundmentioning

confidence: 99%

“…In this frame, a seroprevalence study is an ideal attempt for measuring the true infection rates in general or specific populations (10,14,15) In Italy, a nationwide survey was conducted by the National Institute of Statistics (ISTAT), reporting an IgG seroprevalence of 2.5%. (17).…”

Section: Scientific Backgroundmentioning

confidence: 99%

Population-Based Sero-Epidemiological Study Protocol for the Impact of Smoking on Sars-Cov-2 Infection and Covid-19 Outcomes – The Troina Study

Polosa

Tomaselli

Ferrara

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

After the global spread of severe acute respiratory syndrome coronavirus 2 (SARS−CoV−2), research has highlighted several aspects of the pandemic, focusing on clinical features and risk factors associated with infection and disease severity. However, emerging results on the role of smoking in SARS−CoV−2 infection susceptibility or COVID−19 outcomes are conflicting, and their robustness remains uncertain. In this context, this project aims at quantifying the proportion of SARS−CoV−S antibody seroprevalence, studying the changes in antibody levels over time, and analyzing the association between smoking status and infection using seroprevalence data. The added value of this research is that the current smoking status of the population to be studied will be biochemically verified, in order to avoid the bias associated with self−reported smoking status. As such, the results from this survey may provide actionable metric to study the role of smoking in SARS−CoV−2 spread, and therefore implement the most appropriate public health measures to control the pandemic. The research design involves a 6-month prospective cohort study with serial sampling of the same individuals. Each participant will be surveyed about their demographics and COVID−19−related information, and blood sampling will be collected upon recruitment and at specified follow−up time points (namely, after 8 and 24 weeks). Blood samples will be screened for the presence of SARS−CoV−2 specific antibodies and serum cotinine. Overall, we expect to find a higher prevalence of antibodies in individuals at high−risk for viral exposure (i.e., healthcare or other essential workers), according to previous literature, and to refine current estimates on the association between smoking status and SARS−CoV−2/COVID−19. Our results may serve as a reference for future clinical research and the methodology could be exploited in public health sectors and policies.

show abstract

“…Epidemiological surveillance has primarily focused on hospitalized patients with severe disease, and as such, the full spectrum of the disease, including the extent and proportion of mild or asymptomatic infections, is less clear. Evidence suggests that asymptomatic or oligosymptomatic infection is not uncommon [ 8 - 11 ]. A recent review reported that at least one third of SARS-CoV-2 infections are asymptomatic and that almost three quarters of persons who are asymptomatic at the time of a positive polymerase chain reaction (PCR) test result will remain asymptomatic [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Seroepidemiological Survey on the Impact of Smoking on SARS-CoV-2 Infection and COVID-19 Outcomes: Protocol for the Troina Study

Polosa¹,

Tomaselli²,

Ferrara³

et al. 2021

JMIR Res Protoc

Self Cite

View full text Add to dashboard Cite

Background After the global spread of SARS-CoV-2, research has highlighted several aspects of the pandemic, focusing on clinical features and risk factors associated with infection and disease severity. However, emerging results on the role of smoking in SARS-CoV-2 infection susceptibility or COVID-19 outcomes are conflicting, and their robustness remains uncertain. Objective In this context, this study aims at quantifying the proportion of SARS-CoV-2 antibody seroprevalence, studying the changes in antibody levels over time, and analyzing the association between the biochemically verified smoking status and SARS-CoV-2 infection. Methods The research design involves a 6-month prospective cohort study with a serial sampling of the same individuals. Each participant will be surveyed about their demographics and COVID-19–related information, and blood sampling will be collected upon recruitment and at specified follow-up time points (ie, after 8 and 24 weeks). Blood samples will be screened for the presence of SARS-CoV-2–specific antibodies and serum cotinine, being the latter of the principal metabolite of nicotine, which will be used to assess participants’ smoking status. Results The study is ongoing. It aims to find a higher antibody prevalence in individuals at high risk for viral exposure (ie, health care personnel) and to refine current estimates on the association between smoking status and SARS-CoV-2/COVID-19. Conclusions The added value of this research is that the current smoking status of the population to be studied will be biochemically verified to avoid the bias associated with self-reported smoking status. As such, the results from this survey may provide an actionable metric to study the role of smoking in SARS-CoV-2 infection and COVID-19 outcomes, and therefore to implement the most appropriate public health measures to control the pandemic. Results may also serve as a reference for future clinical research, and the methodology could be exploited in public health sectors and policies. International Registered Report Identifier (IRRID) DERR1-10.2196/32285

show abstract

Occupational Exposure in the Lombardy Region (Italy) to SARS-CoV-2 Infection: Results from the MUSTANG–OCCUPATION–COVID-19 Study

Cited by 21 publications

References 28 publications

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up

Population-Based Sero-Epidemiological Study Protocol for the Impact of Smoking on Sars-Cov-2 Infection and Covid-19 Outcomes – The Troina Study

Seroepidemiological Survey on the Impact of Smoking on SARS-CoV-2 Infection and COVID-19 Outcomes: Protocol for the Troina Study

Contact Info

Product

Resources

About